TL;DR
Glutathione (GSH) is the body’s master antioxidant and the redox foundation that all other longevity interventions depend on. Intracellular GSH declines with age due to dual precursor scarcity (cysteine + glycine), driving mitochondrial dysfunction, inflammation, and insulin resistance. GlyNAC (glycine + NAC, 100 mg/kg/day each) is the most evidence-backed protocol — restores GSH to youthful levels and reverses multiple aging hallmarks in RCTs. Standard oral GSH is nearly useless (destroyed by gut GGT); use liposomal GSH or GlyNAC instead. GSH and NAD+ are co-dependent — fixing one without the other is incomplete.
Why it matters for Vitals
- The redox state GSH maintains is the biochemical background condition that determines whether other repair peptides (GHK-Cu, BPC-157) can bind and signal correctly
- Mitochondrial GSH (mGSH) depletion is a leading indicator of ferroptosis risk — directly detectable via GPX4 activity distortion in wearable oxidative-stress proxies
- GlyNAC benefits (gait speed, grip strength, inflammation, cognition) map directly to Vitals biometric readouts
- GSH elevation during senolytic windows (PCC1, D+Q) buffers the SASP oxidative burst — protective of neighboring cells
Key Facts
| Status | OTC oral/liposomal (GRAS); IV requires clinical setting |
| Class | Endogenous tripeptide / master antioxidant / redox hub / heavy metal chelator |
| Core mechanism | Maintains GSH:GSSG ratio >100:1; Nrf2-ARE activation; GPX4 cofactor for ferroptosis prevention |
| Strongest evidence | GlyNAC RCTs (Sekhar 2021–2024): restored GSH, +78% mitochondrial fat oxidation, improved gait/cognition/inflammation |
| Best oral route | GlyNAC (precursor) or bimodal liposomal — NOT standard oral GSH |
| Key risk | Active malignancy (tumor-protective at this stage); IV metal redistribution; IV endotoxin contamination |
| Withdrawal effect | All GlyNAC benefits reverse within 12 weeks of stopping — continuous use required |
| Evidence level | Multiple human RCTs; strong mechanistic + epidemiologic |
Mechanism Summary
Biosynthesis and the Rate-Limiting Step
GSH is synthesized in two ATP-dependent cytosolic steps:
- GCL (glutamate-cysteine ligase) — rate-limiting; GCLC catalytic + GCLM modifier; bottleneck = cysteine supply (kept low to prevent thiol toxicity)
- GS (glutathione synthetase) — adds glycine; glycine becomes second bottleneck in older adults
Regeneration: GSSG → GSH via glutathione reductase (GR), requiring NADPH from the pentose phosphate pathway. This is where NAD+ and GSH are co-dependent.
Nrf2-ARE Axis
ROS/electrophiles modify Keap1 cysteines → Nrf2 released → nuclear translocation → ARE-driven transcription of GCLC, GCLM, SLC7A11 (xCT). This is why exercise, sauna, and sulforaphane boost GSH — all activate Nrf2.
mGSH — The Critical Mitochondrial Pool
Mitochondria cannot synthesize GSH — import from cytosol via SLC25A39 (primary) and SLC25A40 (macrophage-specific). mGSH is 10–15% of total cellular GSH and is the mandatory cofactor for GPX4 (the only enzyme that reduces lipid hydroperoxides in membranes). mGSH depletion → GPX4 failure → ferroptosis.
Ferroptosis Control
GPX4 is the gatekeeper of ferroptosis — the only enzyme that handles membrane lipid peroxides. It requires mGSH as a cofactor. When mGSH is depleted, GPX4 cannot function → lipid ROS accumulates → iron-dependent regulated necrosis. MitoQ can preserve mitochondrial integrity even when GPX4 is compromised.
What the current evidence suggests
- GlyNAC in older adults (RCT, 16–24 wks): Restored intracellular GSH to young-adult levels; +78% mitochondrial fatty acid oxidation; improved gait speed, grip strength, cognition, DNA damage (8-OHdG), inflammation (CRP/IL-6/TNF-α), insulin resistance, endothelial function
- Liposomal GSH (LipoDuo™ 2026 trial): 1.9× cellular uptake vs plain GSH; 6× peak plasma concentration; maintained >500 ng/mL for 24 hrs
- NAC and cancer risk (2025 COPD cohort): 31% reduction in adjusted HR for breast, prostate, colorectal cancer with long-term use — protective pre-malignancy
- Established malignancy: GSH becomes tumor-protective — cells overexpress GCL/xCT to buffer oxidative stress of rapid proliferation
Risks and Uncertainty
| Risk | Detail |
|---|---|
| Active malignancy | GSH/NAC may shield tumors from oxidative therapy — avoid in this context |
| IV metal redistribution | Rapid mobilization from bone/brain → acute kidney damage or neurological flare; requires baseline kidney function + mineral panel |
| IV endotoxin contamination | FDA 2019 warning on compounded IV GSH (200 mg/mL) — caused fever/chills/hypotension |
| Withdrawal effect | All GlyNAC benefits revert within 12 wks of stopping — substrate supplementation must be continuous |
| mGSH gap | Systemic GSH support does not guarantee mGSH restoration — oral + exercise + Nrf2 activation all contribute |
| Confidence level | Moderate-high for GlyNAC (human RCTs); moderate for liposomal (2026 trial); high for cancer paradox (mechanistic + epidemiologic) |
Best Stack Context
- GlyNAC + NMN/NAD+: NADPH from NAD+ drives GSH regeneration; GSH depletion accelerates NAD+ loss — address both together
- GSH + SLU-PP-332: More mitochondria = more baseline ROS; GSH acts as coolant allowing mitochondrial biogenesis benefits without oxidative accumulation
- GSH + PCC1 (senolytic window): Buffers ROS/SASP burst when senescent cells are cleared; protects bystander cells
- GSH + GHK-Cu / BPC-157: Maintains reduced intracellular environment needed for GHK-Cu copper coordination and BPC-157 NO/VEGF signaling
- GSH + Rapamycin: Buffers autophagy-associated ROS during rapamycin’s organelle cleanup phase
- GSH + Epithalon: mGSH preserves OXPHOS capacity needed for telomere elongation machinery
Comparison to Related Compounds
| Compound | Class | Overlap with GSH |
|---|---|---|
| NMN NAD+ | NAD+ precursor | Co-dependent via NADPH/GR pathway |
| SLU-PP-332 | ERR agonist | GSH buffers ROS from mitochondrial biogenesis |
| PCC1 | Senolytic | GSH protects bystander cells during senolysis |
| GHK-Cu | Copper tripeptide | GSH maintains reduced environment for receptor binding |
| Rapamycin | mTOR inhibitor | GSH buffers autophagy-associated oxidative stress |
Dosing Summary
| Protocol | Route | Dose | Frequency |
|---|---|---|---|
| GlyNAC (first-line) | Oral | 100 mg/kg/day glycine + 100 mg/kg/day NAC | Daily, continuous |
| Liposomal GSH | Oral | Seek bimodal/liposomal formulation | Daily |
| SubQ (lyophilized) | SubQ | 200–600 mg/injection | 2–3×/week |
| IV (clinical) | IV | In clinical setting with monitoring | Pulse cycles |
Standard oral GSH: avoid — GGT in intestinal brush border destroys >90% before cellular uptake.
Links
- Peptides MOC
- NMN NAD+ — NADPH/GR co-dependency
- PCC1 — senolytic window GSH support
- SLU-PP-332 — ROS buffering for mitochondrial biogenesis
- GHK-Cu — reduced environment for receptor binding
- BPC-157 — NO/VEGF signaling environment
- Rapamycin — autophagy ROS support
- Senolytic mechanisms — shared senotherapeutic context
Source: Gemini Deep Research · Sekhar et al. GlyNAC RCTs 2021–2024 · LipoDuo™ liposomal 2026 trial · SLC25A39/40 transporter 2024–2025 · NAC cohort cancer risk 2025 · FDA 2019 IV GSH warning